Investors of REGENXBIO Inc. Urged to Join Class Action Lawsuit for Recovering Losses

Attention REGENXBIO Inc. Investors

Investors who have suffered losses in REGENXBIO Inc. (NASDAQ: RGNX) should be aware of a pending class action securities lawsuit facilitated by the renowned law firm Levi & Korsinsky, LLP. This legal action aims to compensate those adversely affected by the company's alleged securities fraud that transpired between February 9, 2022, and January 27, 2026.

The Allegations Against REGENXBIO

The crux of the lawsuit focuses on misleading information relating to REGENXBIO's gene therapy product candidate, RGX-111, intended for the treatment of severe Mucopolysaccharidosis Type I, commonly referred to as Hurler syndrome. The complaint alleges that while the company touted optimistic assertions regarding RGX-111's clinical trial outcomes, it simultaneously suppressed critical information that raised concerns about the therapy's efficacy and safety.

In particular, the lawsuit suggests that the company's positive announcements about RGX-111's biomarker and safety data were undercut by serious safety issues revealed towards the end of January 2026. Notably, on January 28, 2026, REGENXBIO had to issue a press release confirming that the FDA had placed a clinical hold on RGX-111 after a participant in the ongoing Phase I/II trial developed an intraventricular CNS tumor. Consequently, this news caused REGENXBIO's stock price to plummet from $13.41 to $11.01 in just one day, marking a steep 17.8% drop.

How to Participate in the Class Action

If you invested in REGENXBIO during the specified timeframe and experienced financial losses, you have the opportunity to join this class action suit. Potential plaintiffs have until April 14, 2026, to request court approval to serve as lead plaintiff. However, participating does not necessitate serving as lead plaintiff, allowing investors to claim potential damages without personal obligations or costs.

Why Levi & Korsinsky?

With over 20 years of legal experience in securities litigation, Levi & Korsinsky has successfully secured hundreds of millions for shareholders. The firm prides itself on its impressive track record and expert representation in complex cases like this. In fact, for seven consecutive years, they have been recognized in ISS Securities Class Action Services' Top 50 Report as one of the leading securities litigation firms in the United States.

Contact Information

Investors wishing to learn more or enroll in the class action can visit Levi & Korsinsky's website for more details. Alternatively, they can reach out via email to Joseph E. Levi, Esq. at [email protected] or by calling (212) 363-7500.

Final Thoughts

This is a critical time for affected investors to consider their options following the unfortunate developments surrounding REGENXBIO. The actions taken now can potentially lead to recovery of significant losses. Remember, joining the class action can give you a voice in seeking accountability for your financial setbacks. Don't miss this opportunity for justice and potential recuperation of your investment losses.